PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-5.04%
Revenue decline while Medical - Pharmaceuticals median is 0.44%. Seth Klarman would investigate if market share loss is temporary.
-5.05%
Cost reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive advantage potential.
-4.96%
Gross profit decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
0.07%
Margin change of 0.07% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.62%
Other expenses change of 36.62% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
3.03%
Operating expenses growth near Medical - Pharmaceuticals median of 2.82%. Charlie Munger would verify industry norms.
-3.88%
Total costs reduction while Medical - Pharmaceuticals median is 3.43%. Seth Klarman would investigate advantages.
-8.70%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
34.45%
D&A change of 34.45% versus flat Medical - Pharmaceuticals D&A. Walter Schloss would verify adequacy.
-21.69%
EBITDA decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-17.54%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-24.23%
Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-20.21%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
23.47%
Other expenses change of 23.47% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
-21.76%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-17.61%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-21.25%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-22.15%
Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-18.02%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-22.17%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-22.17%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.
No Data
No Data available this quarter, please select a different quarter.